A Phase 2, Single-arm, Open-label Study to Evaluate the Safety and Efficacy of Niraparib Combined With Bevacizumab as Maintenance Treatment in Patients With Advanced Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer Following Front-line Platinum-based Chemotherapy With Bevacizumab
Latest Information Update: 06 Sep 2024
At a glance
- Drugs Bevacizumab (Primary) ; Niraparib (Primary)
- Indications Carcinoma; Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
- Focus Therapeutic Use
- Acronyms OVARIO
- Sponsors GlaxoSmithKline; GSK; TESARO
- 04 Sep 2024 Status changed from active, no longer recruiting to completed.
- 23 Nov 2022 Planned End Date changed from 18 Nov 2022 to 31 May 2024.
- 08 Jun 2022 Results published in the Gynecologic Oncology